D9078C00001

Research code: D9078C00001
Research name: Randomized, double-blind, placebo-controlled, multicenter, international Phase III study evaluating durvalumab in combination with oleclumab and durvalumab with monalizumab in patients with locally advanced (stage III), unresectable non-small cell lung cancer ( NSCLC) who did not progress after radical, platinum-based, simultaneous chemoradiotherapy (PACIFIC-9)
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with small cell lung cancer, for concurrent chemotherapy-radiotherapy
Research drug: durvalumab